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THE initial response of the host to noxious stimuli pro-
duces a nonspecific inflammatory response. A more speci-
fic immune response is believed to be modulated by two
classes of molecules: lipid mediators (PG, LT and PAF)
and cytokines, synthesized by phagocytes and parenchy-
real cells. In this review we discuss the increasing evi-
dence of the interrelationship between eicosanoids, PAF
and cytokines: IL-1 and TNF induce PG synthesis in
various cells and PG, in turn, modulate cytokine produc-
tion. We focused on the regulatory effects of LTB4, PGE
and PAF on cytokine gene expression.
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When confronted with a variety of noxious
stimuli, the host responds by producing an array of
soluble factors and by mobilizing various cell
populations. In most instances, the initial response
is relatively nonspecific and consists of various
degrees of inflammation. Among the soluble
mediators which participate in this inflammatory
response and which may also modulate the
subsequent more specific immune response, two
classes of molecules have emerged as the principal
protagonists" lipid mediators, derived from cell
membrane phospholipids, and cytokines, synthe-
sized by phagocytes and parenchymal cells.
Within minutes of stimulation, eicosanoids such
as prostaglandins (PG) and leukotrienes (LT), as
well as platelet activating factor (PAF) are pro-
duced by the action of phospholipase a2 (PLA2) on
the membrane phospholipid 1-0-alkyl-2-arachidon-
oyl-sn-glycero-3-phosphocholine and subsequent
oxidative metabolism of the freed arachidonic acid
or acetylation of the remaining 1-alkyl-2-1yso-
glycerophosphocholine (lyso-PAF) molecule, re-
spectively. These lipid mediators in turn can act on
a variety of cell populations, often, including the
cells which produced them. Their bioactions are
thought to be mediated by specific cell membrane
receptors. Recently, a PAF receptor from guinea-
pig lung has been cloned
2 and its proposed structure
suggests that it is associated with a G protein.
Functional studies had previously suggested that
this may also be the case with LTB4 receptors.
Postreceptor events and signal transduction path-
ways in cellular responses triggered by LT, PG
and PAF are objects of intense research using
metabolic inhibitors and receptor antagonists. In
the present review, we will focus on the regulatory
effects of LTB4, PGE2 and PAF on cytokine gene
expression (Table 1).
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Table 1. Summary of actions of eicosanoids and PAF on
cytokine gene regulations.
Cytokine Mediator Transcription mRNA Protein
TNF LTB4 1"
PGE2 (low dose) 1" 1"
PGE2 (high dose)
PAF 1"
IL-1 LTB4 I" I" __+
PGE2
PAF T I’
IL-6 LTB, T T T
Tumour Necrosis Factor (TNF=)
TNFz is a cytokine produced preferentially by
activated macrophages, but also by NK cells and
neutrophils. TNFz may play a role in immune
modulation4 and anti-tumour defences, in addition
to being a potent mediator for numerous
inflammatory responses, such as endotoxic shock,
adult respiratory distress syndrome and bowel
necrosis.
-8 In these conditions, however, synergy
with other mediators, including PAF, may be
needed for expression of disease.
When human monocytes are exposed to graded
concentration of LTB4, their cell-free supernatants
contain increased amounts of TNFcz which peaks at
8-16 h. The maximal effect of LTB4 is observed at
concentrations of 10-1 M. Endogenous lipoxy-
genase metabolites may also be involved in
enhanced TNFz production following some
stimuli, such as silica, asbestos,
1 PAF
11 or
lipopolysaccharide (LPS).
2 Evidence for such an
involvement is derived from use of 5-1ipoxygenase
(5-LO) inhibitors which can partially or totally
block TNFz production. Addition of exogenous
LTB4 can restore TNFz production under certain
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circumstances.
11 In contrast, inhibition of 5-LO
activation using MK-886, which binds the 5-
lipoxygenase-activating protein (FLAP), does not
affect TNF production
13 in response to phorbol
ester, Concanavalin A, LPS or zymosan. TNFo
gene expression can be stimulated by phorbol
esters, LPS or TNFo itself. Under these conditions,
inhibition of PLA2 by bromophenacyl bromide or
quinacrine, or of lipoxygenases by ketoconazole or
nordihydroguaiaretic acid (NDGA) results in
inhibition of TNFo mRNA accumulation and
TNFo gene transcription.
14<6 On the other hand,
exogenous LTB4 increases TNFz mRNA. 14 Inter-
estingly, the dual cyclooxygenose (CO)/5-LO
inhibitor, tebufelone, at 20-25/M, inhibits TNFo
mRNA accumulation while enhancing TNFo
production.
7
In comparison to 5-LO metabolites, CO
metabolites such as PGE2 have been shown to
inhibit TNFo production at high concentra-
tions,18’19 presumably by augmenting cAMP levels
in the cells. Low concentrations of PGE2, however,
appear to stimulate guanylate cyclase and result in
augmented TNFo production.2’21 TNF mRNA
accumulation is also inhibited by PGE2,
22 an effect
associated with decreased TNF transcription
14
(Fig. 1).
PAF can enhance TNFo production by rat
alveolar macrophages
11 and human monocytes
23-2s
and myeloid cells.
26 In the macrophages, the
activation pathway may involve 5-LO, since
inhibitors such as NDGA or AA-861 can abrogate
the effect of PAF.
1 In human monocytes and
myeloid cell lines, the involvement of the 5-LO
pathway in PAF-mediated TNFo production is still
unclear. PAF induces, however, a bimodal
dose-response pattern in these cells, with both a
nanomolar and a femtomolar concentration peak of
activation.2 Enhanced accumulation of TNF
mRNA is maximally stimulated by 10
-13 and 10 -7
M PAF in monocytes and in HL-60 promyelocytic
leukemia cells induced by 1,25 (OH)2 vitamin D3 to
differentiate into macrophages.
2
PAF LTB4
PGE2
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FIG. 1. Schematic representation of cytokine gene regulation by
eicosanoids and PAF, involving cyclic nucleotides.
Interleukin-1 (IL-1)
IL-1 is a key protagonist of immune and
inflammatory events, being involved, among other
effects, in T-cell activation by accessory cells and in
induction of fever and other features of inflamma-
tion.
iv It is produced principally by mono-
cytes/macrophages,
28 but also by a variety of other
cell types such as B-cells, endothelial cells,
keratinocytes, polymorphonuclear (PMN) leuko-
cytes, etc. There are two species of IL-1, designated
IL-lo and IL-lfl, which share cell receptors and
have similar bioactions in spite of being derived
from two separate genes.
Addition of exogenous LTB4 to monocytes
stimulates IL-1/ transcription and mRNA accumu-
lation (Rola-Pleszczynski and Stankova, in prepara-
tion), but little IL-1 protein release.29 Earlier reports
that IL-1 activity was enhanced in supernatants
from LTB4-treated monocytes
3 were consistent
with measures of both IL-1 and IL-6 in bioassays
of lymphocyte activating factor (LAF) activity in
monocyte supernatants.29’3
Prostaglandins, on the other hand, have been
known for some time to inhibit lymphokine
secretion.
32 PGE2 inhibits IL-1 production by
monocytes via a post-transcriptional mechanism
involving increased cAMP levels within the cell.
33
PGE2 also inhibits secretion of IL-1 by large
granular lymphocyte (LGL)
34 but has no direct
effect on IL-1 secretion by phagocytic cells of the
thymic reticulum
35 or by peritoneal macrophages.
3
While PGE2 inhibits TNF mRNA accumulation
in monocytes, it has no effect on IL-lo or IL-lfl
mRNA levels.
2
PAF stimulates IL-lo and IL-lfl production in
human monocytes in a concentration-dependent
manner, in synergy with other stimuli such as LPS,
MDP or IPN.24’37-39 As with TNFo, IL-1
production in PAF-treated monocytes follows a
bimodal pattern, with peak activities at 10
-13 and
10-8 M P_AF.24’39 In rats treated with a continuous
infusion of PAF via an osmotic mini-pump, IL-1
production by splenic macrophages was enhanced
by lower doses of PAF, while higher doses had an
inhibitory effect.
4 At the present time, it is unclear
whether PAF regulates IL-lo and IL-lfi production
via transcriptional or post-transcriptional mechan-
isms. IL-lfl mRNA expression in THP-1 cells,
however, can be enhanced by 10-1 M PAF.
41
Interleukin-6
IL-6 is a multifunctional cytokine produced by
monocytes, macrophages, endothelial cells, fibro-
blasts, keratinocytes, T-cells and some tumour cells.
Its numerous synonyms reflect its various biological
activities, as B-cell stimulatory factor 2, interferon
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#2, hybridoma-plasmacytoma growth factor, hepa-
tocyte-stimulating factor.
42-46 IL-6 is an important
regulator of T- and B-cell functions, haematopoiesis
and acute phase responses. 47’48 Infectious agents,
endotoxin and the inflammatory cytokines TNF0
and IL-1 can induce IL-6 production, while
dysregulation of IL-6 expression is associated with
certain chronic inflammatory, autoimmune and
haematopoietic disorders. The findings that IL-6
production is associated with inflammatory states
suggests that its production may also be modulated
by inflammatory lipid mediators.
When human monocytes are cultured in the
presence of graded concentrations of LTB4, a
significant stimulation of production of bioactive
and immunoreactive IL-6 is observed. 29’31 Nanomo-
lar concentrations of LTB4 are optimal, while the
c0-oxidation products 20-OH-LTB4 and 20-COOH-
LTB4 are only 22% and 2% effective, respectively.
LTB4 induces an accumulation of IL-6 mRNA in
treated monocytes with a superposable dose-
response, and maximal accumulation at 1 h. While
IL-6 mRNA half-life in untreated ceils is
approximately 1 h, it is extended to 3h in
LTB4-treated monocytes. Moreover, nuclear tran-
scription of IL-6 mRNA is augmented at 30 min by
a factor of five in LTB4-treated cells. Furthermore,
LTB4-treated monocytes contain a nuclear protein
factor (NF) which binds to a promoter region of
the IL-6 gene, called NF-IL-6-binding domain, and
which may be involved, among other factors, in
LTB4-mediated induction of IL-6 gene transcrip-
tion.
31
PAF can also stimulate IL-6 production by
human monocytes in the picomolar range and this
stimulation is enhanced by prior treatment with
TNF0 or IFN/.
49 In contrast, rat alveolar
macrophages require a second stimulus, such as
LPS or MDP, to respond to PAF with augmented
IL-6 production.
5 This augmented production is
brought down to baseline by pretreatment of the
cells with the FLAP inhibitor MK-886 or the 5-LO
inhibitor AA-861, suggesting that under these
conditions, the action of PAF is mediated by
endogenous 5-LO metabolites. Human PMN and
endothelial cells can also respond to PAF with
enhanced IL-6 production and IL-6 mRNA
accumulation (unpublished).
Conclusions
There is increasing evidence to suggest that the
production of eicosanoids, PAF and cytokines may
be interrelated: IL-1 and TNF induce PG synthesis
in various cells
51-53 and PG, in turn, modulate
cytokine production, as discussed in this review. In
contrast, LT can augment IL-1, IL-6 and TNF
production and endogenous LT production may
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FIG. 2. Schematic representation of mutual regulatory pathways between
TNF, IL-1 and IL-6. (A) Proposed preferential involvement of 5-LO in
11-6 production. (B) Proposed mechanism of action of 5-LO inhibitors
in suppressing the negative feed-back of IL-6 on TNF and IL-1
production.
play a role in TNF and IL-6 synthesis. IL-1, TNF
and IFN can also induce the synthesis of PAF in
several cell types, including endothelial cells,
neutrophils and macrophages,
54-56 while PAF can,
in turn, augment IL-1, IL-6 and TNF production
by rat and human cells. Such a positive feedback
loop at this level, with potential for amplification
of immune or inflammatory responses, may be
counterbalanced by the negative feedback action of
IL-6 on both IL-1 and TNF. 57’58 This negative
feedback may account for the limited production of
IL-1 by LTB4-stimulated monocytes which readily
produce large amounts of IL-6. It may also explain
the augmented production of IL-1 and TNF
observed after treatment of monocytes with a dual
CO/5-LO inhibitor, a treatment which may
preferentially inhibit IL-6 production (Fig. 2).
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